Anushree Chaitanya Shirali, MD
Associate Professor of Medicine; Medical Director, Peritoneal Dialysis Unit; Medical Director, Hemodialysis Unit
Research & Publications
Biography
News
Coauthors
Selected Publications
- Onconephrology: Core Curriculum 2023Yarandi N, Shirali A. Onconephrology: Core Curriculum 2023. American Journal Of Kidney Diseases 2023, 82: 743-761. PMID: 37855786, DOI: 10.1053/j.ajkd.2023.04.014.
- How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 InhibitorsGunasekaran D, Shirali A. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors. Kidney360 2023, 4: e1322-e1324. PMID: 37487034, PMCID: PMC10550005, DOI: 10.34067/kid.0000000000000219.
- Onco-Nephrology Kidney Disease in the Cancer PatientYarandi N, Shirali A. Onco-Nephrology Kidney Disease in the Cancer Patient. Medical Clinics Of North America 2023, 107: 749-762. PMID: 37258012, DOI: 10.1016/j.mcna.2023.03.007.
- Immune Checkpoint Inhibitors: Immunobiology and Immune-related Adverse EventsShirali, AC and Karam S. Immune Checkpoint Inhibitors: Immunobiology and Immune-related Adverse Events. In the American Society of Nephrology Onco-nephrology Curriculum. Eds. Letcha, S and N Leung. 2023. Available on-line at https://education.asn-online.org/course/view.php?id=1205&pageid=2815
- Chemotherapy-Associated Thrombotic MicroangiopathyAklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.
- Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARYShirali AC. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY. Kidney360 2022, 3: 806-808. PMID: 36129422, PMCID: PMC9438420, DOI: 10.34067/kid.0005592021.
- Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapyBaker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.
- Pathogenesis of Acute Tubulointerstitial NephritisAron A, Krishnan N, Shirali A. Pathogenesis of Acute Tubulointerstitial Nephritis. 2022, 21-47. DOI: 10.1007/978-3-030-93438-5_3.
- Cancer Drug Dosing in Chronic Kidney Disease and DialysisShirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.
- Venous outflow banding for maturation of a percutaneous arteriovenous fistulaBarahona M, Tonnessen B, Cardella J, Shirali A, Perez-Lozada JC, Chaar C. Venous outflow banding for maturation of a percutaneous arteriovenous fistula. Journal Of Vascular Surgery Cases And Innovative Techniques 2022, 8: 42-44. PMID: 35079669, PMCID: PMC8777140, DOI: 10.1016/j.jvscit.2021.12.007.
- Pathogenesis of Acute Tubulointerstitial NephritisAron, A.W., Krishnan, N., Shirali, A.C. (2022). Pathogenesis of Acute Tubulointerstitial Nephritis. In: Tubulointerstitial Nephritis, Atta, M.G., Perazella, M.A. (eds). Springer, Cham.
- Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure SyndromeQuraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.
- Lysozyme nephropathy: A rare and reversible cause of acute kidney injury in chronic myelomonocytic leukemiaDonati A, Luciano R, Shirali A. Lysozyme nephropathy: A rare and reversible cause of acute kidney injury in chronic myelomonocytic leukemia. Journal Of Onco-Nephrology 2021, 5: 120-121. DOI: 10.1177/23993693211026926.
- Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter StudyCortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study. Journal Of The American Society Of Nephrology 2020, 31: 435-446. PMID: 31896554, PMCID: PMC7003302, DOI: 10.1681/asn.2019070676.
- 30 Tumor lysis syndromeRASTEGAR M, KITCHLU A, SHIRALI A. 30 Tumor lysis syndrome. 2020, 275-280.e3. DOI: 10.1016/b978-0-323-54945-5.00039-4.
- Tumor Lysis SyndromeRastegar M, Abhijat K, Shirali A, Tumor lysis syndrome. In: Onco-Nephrology, Kevin W. Finkel, Mark A. Perazella, Eric P. Cohen (eds.), , Elsevier, 2020.
- Drug-induced NephropathiesAnushree Shirali and Mark A. Perazella, 'Drug-induced nephropathies', in Neil N. Turner and others (eds), Oxford Textbook of Clinical Nephrology: Three-Volume Pack, 4 edn (Oxford, 2019; online edition update)
- High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?Kitchlu A, Shirali A. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best? Journal Of Onco-Nephrology 2019, 3: 11-18. DOI: 10.1177/2399369319827305.
- Drug-induced nephropathiesAnushree Shirali and Mark A. Perazella, 'Drug-induced nephropathies', in Neil N. Turner and others (eds), Oxford Textbook of Clinical Nephrology: Three-Volume Pack, 4th edn (Oxford, 2018; online edition update)
- 35 Kidney Disease Caused by Therapeutic AgentsPerazella M, Shirali A. 35 Kidney Disease Caused by Therapeutic Agents. 2018, 334-344. DOI: 10.1016/b978-0-323-47794-9.00035-4.
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer PatientsShirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal Of Kidney Diseases 2016, 68: 287-291. PMID: 27113507, DOI: 10.1053/j.ajkd.2016.02.057.
- Nephrotoxicity of Chemotherapy AgentsValika A, Shirali A. Nephrotoxicity of Chemotherapy Agents. 2015, 65-91. DOI: 10.1007/978-1-4939-2659-6_4.
- Nephrotoxicity of Chemotherapy AgentsIn OncoNephrology: Cancer, Chemotherapy, and the Kidney Kenar Jhaveri MD and Abdulla Salahudeen MD, Editors Springer, New York, NY
- Drug-Induced NephropathiesAnushree Shirali and Mark A. Perazella, 'Drug-induced nephropathies', in Neil N. Turner and others (eds), Oxford Textbook of Clinical Nephrology: Three-Volume Pack, 4 edn (Oxford, 2015; online edn, Oxford Academic, 1 Oct. 2015), https://doi.org/10.1093/med/9780199592548.003.0362.
- 37 Kidney Disease Caused by Therapeutic AgentsPerazella M, Shirali A. 37 Kidney Disease Caused by Therapeutic Agents. 2014, 326-336. DOI: 10.1016/b978-1-4557-4617-0.00037-6.
- Impaired NLRP3 inflammasome activity in elderly hosts contributes to the prevalence of primary and secondary Streptococcus pneumoniae infection. (114.4)Stout-Delgado H, Shirali A, Jaramillo R, Harrod K. Impaired NLRP3 inflammasome activity in elderly hosts contributes to the prevalence of primary and secondary Streptococcus pneumoniae infection. (114.4). The Journal Of Immunology 2012, 188: 114.4-114.4. DOI: 10.4049/jimmunol.188.supp.114.4.
- 287 Nanoparticle Encapsulated Mycophenolic Acid Delays Murine Skin Allograft Rejection without Toxic Drug EffectsShirali A, Look M, Fahmy T, Goldstein D. 287 Nanoparticle Encapsulated Mycophenolic Acid Delays Murine Skin Allograft Rejection without Toxic Drug Effects. American Journal Of Kidney Diseases 2011, 57: b88. DOI: 10.1053/j.ajkd.2011.02.290.
- Acute RejectionShirali, A.C., Goldstein, D.R. (2009). Rejection, Acute. In: Lang, F. (eds) Encyclopedia of Molecular Mechanisms of Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29676-8_37
- Rejection, AcuteShirali A, Goldstein D. Rejection, Acute. 2009, 1814-1817. DOI: 10.1007/978-3-540-29676-8_37.
- Acid-base Homeostasis in Children With Growth Hormone DeficiencyGlaser N, Shirali A, Styne D, Jones K. Acid-base Homeostasis in Children With Growth Hormone Deficiency. Pediatrics 1998, 102: 1407-1414. PMID: 9832577, DOI: 10.1542/peds.102.6.1407.